Last reviewed · How we verify
BoNT-A
BoNT-A is a Small molecule drug developed by Al Mouwasat Hospital. It is currently FDA-approved. Also known as: Botulinum toxin A, Botulinum neurotoxin type A, IncobotulinumtoxinA, Experimental intervention.
BoNT-A, also known as Botulinum Toxin Type A, has been studied for various conditions including Migraine Disorders, Chronic Disease, Thoracic Outlet Syndrome, Overactive Bladder, and Urinary Urge Incontinence. It is administered through injections, often with normal saline as a control, in clinical trials to assess its efficacy for these conditions.
At a glance
| Generic name | BoNT-A |
|---|---|
| Also known as | Botulinum toxin A, Botulinum neurotoxin type A, IncobotulinumtoxinA, Experimental intervention, Botox |
| Sponsor | Al Mouwasat Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- DaxibotulinumtoxinA for Blepharospasm (PHASE2)
- IncobotulinumtoxinA for Provoked Vestibulodynia With Overactive Pelvic Floor Muscle Dysfunction (PHASE2)
- Prospective, Non-interventional Study Assessing Periorbital Rejuvenation Procedure
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine (PHASE3)
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine (PHASE3)
- Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury (PHASE3)
- IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia (PHASE3)
- Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing With Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BoNT-A CI brief — competitive landscape report
- BoNT-A updates RSS · CI watch RSS
- Al Mouwasat Hospital portfolio CI
Frequently asked questions about BoNT-A
What is BoNT-A?
Who makes BoNT-A?
Is BoNT-A also known as anything else?
What development phase is BoNT-A in?
Related
- Manufacturer: Al Mouwasat Hospital — full pipeline
- Also known as: Botulinum toxin A, Botulinum neurotoxin type A, IncobotulinumtoxinA, Experimental intervention, Botox
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing